15th International Conference on

Pharmacology

Scientific Program

Jyoti Sharma

Jyoti Sharma

Department of Pharmacology, India

Title: EVALUATION OF ANTI-ANXIETY AND ANTI-DEPRESSANT EFFECT OF PALONOSETRON IN SWISS ALBINO MICE

Biography:

Dr. Jyoti Sharma, currently working as Assistant Professor in the Department of Pharmacology, PGIMS, Rohtak. Actively involved in teaching of MD, MBBS, BDS & Allied Health Sciences. Work profile also includes Detection & reporting of ADRs, Quality assurance (e.g. completeness and integrity of data) of uploaded ADRs, Assessment of Individual Case Safety Reports, Causality assessment, Clinical and experimental Research. Has a total of 7 years of teaching experience. Recipient of Dr.  R.  D  Kulkarni  Award  for  Third  position  in  Poster  presentation  at  South  Asian  College  of  Clinical  Pharmacology  an  Affiliate  of  American  College  of  Clinical  Pharmacology in  Eleventh  Annual  Conference  “Clinical  Pharmacology:  Contributing  to  Global  Health and  Policies”  held  from  29th  April  –  2nd  May  2018. The above study was done to find out the anxiolytic and antidepressant effect of Palonosetron as no studies have been found till date.

Abstract

Background: Depression and anxiety remain serious problems in given unexpected circumstances like Covid-19. Serotonin is one of the most important neurotransmitters influencing mental health and a potential target for pharmacological treatments. 5HT3 receptor antagonists like ondansetron; mainly used for management of acute & delayed cancer chemotherapy induced emesis, has shown anxiolytic and antidepressant effect in various studies. Another 5HT3 antagonist; Palonosetron approved for delayed cancer chemotherapy induced emesis, has yet not been studied for anxiolytic and antidepressant effects.
Material & Methods: Light-dark compartment model was used for anti-anxiety effect evaluation and Swim despair test was used for evaluation of anti-depressant effect. Swiss albino mice were used and randomly divided in 5 groups of 6 each to receive following 5 treatments: Group 1Control i.e normal saline (0.1 ml/10 g of body weight i.p.), Group 2: Diazepam (1mg/kg i.p), Group 3: Fluoxetine (18mg/kg i.p), Group 4:  Palonosetron (0.025 mg/kg i.p), Group 5: Palonosetron (0.05mg/kg i.p) in each animal model. In light-dark compartment model efficacy was assessed at end of 15, 30, 60, 120, 180 & 300mins by observing time spent in light compartment and number of transitions made between both compartments. In Swim despair test efficacy was assessed by recording of immobility period after 1 hr & 24 hrs of drug administration.
Results: Time spent in the light compartment at the end of 30, 60 and 120 min with palonosetron (0.05mg/kg) was statistically significant more as compared to control & fluoxetine.  No of transitions made between both compartments also increased with palonosetron (0.05mg/kg) at the end of 15, 30, 60 & 120 mins as compared to control and fluoxetine groups. In Swim despair test palonosetron (0.05mg/kg) showed statistically significant antidepressant activity as compared to control and fluoxetine group at 1 hr & 24 hrs respectively.
Conclusion: Palonosetron (0.05mg/Kg) possesses significant antidepressant & anti-anxiety activity in animal models.

  • Cancer Pharmacology
  • Cardiovascular Pharmacology
  • Clinical Pharmacology
  • Network Pharmacology
  • Invitro and Invivo Drug Delivery Techniques
  • Chemotherapy
  • Digital Pills-Pharmaceutical Technology
  • Pharmacology-Pharmacokinetics & Pharmacodynamic approach
  • Animal Pharmacology